首页> 美国卫生研究院文献>American Journal of Physiology - Gastrointestinal and Liver Physiology >β-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes
【2h】

β-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes

机译:β-Klotho和FGF-15 / 19抑制肠上皮细胞和胆管细胞中根尖钠依赖性胆汁酸转运蛋白

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

β-Klotho, a newly described membrane protein, regulates bile acid synthesis. Fibroblast growth factor-15 (FGF-15) and FGF receptor-4 (FGFR4) knockout mice share a similar phenotype with β-Klotho-deficient mice. FGF-15 secretion by the intestine regulates hepatic bile acid biosynthesis. The effects of β-Klotho and FGF-15 on the ileal apical sodium bile transporter (ASBT) are unknown. β-Klotho siRNA treatment of the mouse colon cancer cell line, CT-26, and the human intrahepatic biliary epithelial cells (HIBEC) resulted in upregulation of endogenous ASBT expression that was associated with reduced expression of the farnesoid X receptor (FXR) and the short heterodimer partner (SHP). Silencing β-Klotho activated the ASBT promoter in CT-26, Mz-ChA-1 (human cholangiocarcinoma), and HIBEC cells. Site-directed mutagenesis of liver receptor homolog-1 (mouse) or retinoic acid receptor/retinoid X receptor (RAR/RXR) (human) cis-elements attenuated the basal activity of the ASBT promoter and abrogated its response to β-Klotho silencing. siSHP, siFXR, or dominant-negative FXR treatment also eliminated the β-Klotho response. FGF-15 secretion into cell culture media by CT-26 cells was diminished after siFGF-15 or siβ-Klotho treatment and enhanced by chenodeoxycholic acid. Exogenous FGF-19 repressed ASBT protein expression in mouse ileum, gallbladder, and in HIBEC and repressed ASBT promoter activity in Caco-2, HIBEC, and Mz-ChA-1 cells. Promoter repression was dependent on the expression of FGFR4. These results indicate that both β-Klotho and FGF-15/19 repress ASBT in enterocytes and cholangiocytes. These novel signaling pathways need to be considered in analyzing bile acid homeostasis.
机译:β-Klotho是一种新描述的膜蛋白,可调节胆汁酸的合成。剔除成纤维细胞生长因子15(FGF-15)和FGF受体4(FGFR4)的小鼠与缺乏β-Klotho的小鼠具有相似的表型。肠道分泌的FGF-15调节肝胆酸的生物合成。 β-Klotho和FGF-15对回肠顶胆钠转运蛋白(ASBT)的影响尚不清楚。 β-KlothosiRNA对小鼠结肠癌细胞株CT-26和人肝内胆管上皮细胞(HIBEC)的处理导致内源性ASBT表达上调,这与法呢素X受体(FXR)的表达降低有关。短异二聚体伙伴(SHP)。沉默β-Klotho可激活CT-26,Mz-ChA-1(人胆管癌)和HIBEC细胞中的ASBT启动子。肝脏受体homolog-1(小鼠)或视黄酸受体/类维生素X受体(RAR / RXR)(人)顺式元件的定点诱变减弱了ASBT启动子的基础活性并废除了其对β-Klotho沉默的反应。 siSHP,siFXR或显性阴性FXR处理也消除了β-克洛索效应。 siFGF-15或siβ-Klotho处理后,由CT-26细胞向细胞培养基中分泌的FGF-15分泌减少,而鹅去氧胆酸则增强了这种分泌。外源FGF-19抑制小鼠回肠,胆囊和HIBEC中的ASBT蛋白表达,并抑制Caco-2,HIBEC和Mz-ChA-1细胞中的ASBT启动子活性。启动子抑制依赖于FGFR4的表达。这些结果表明,β-Klotho和FGF-15 / 19均抑制肠上皮细胞和胆管细胞中的ASBT。在分析胆汁酸稳态时,需要考虑这些新颖的信号通路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号